Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 21 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS: In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS: After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P = 0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS: A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.).
Overview
CoChat Summary
## TL;DR
In this randomized, placebo-controlled trial of adults with obesity who first lost weight on an 8-week low-calorie diet, exercise plus liraglutide maintained weight loss better than either treatment alone. The combination also produced broader metabolic benefits, including improved body-fat percentage, glycated hemoglobin, insulin sensitivity, cardiorespiratory fitness, and physical functioning.
## Key findings
- After the 8-week low-calorie diet, 195 participants had a mean body-weight decrease of 13.1 kg; these participants were randomized to 1 year of treatment.
- At 1 year, compared with placebo, mean weight change differed by -4.1 kg with exercise, -6.8 kg with liraglutide, and -9.5 kg with the combination.
- The combination reduced body-fat percentage by 3.9 percentage points, versus -1.7 percentage points compared with exercise and -1.9 percentage points compared with liraglutide; it was the only strategy associated with improvements in glycated hemoglobin, insulin sensitivity, and cardiorespiratory fitness.
- Mean total weight loss from baseline to end of trial was 15.7% in the combination group, 10.9% with exercise, 13.4% with liraglutide, and 6.7% with placebo.
## Methods
- Investigator-initiated, randomized, head-to-head, placebo-controlled trial at Hvidovre Hospital and the University of Copenhagen; participants were randomized in a 1:1:1:1 ratio after an 8-week 800-kcal/day low-calorie diet.
- Sample: adults 18 to 65 years with obesity (BMI 32 to 43) and no diabetes; 215 started the diet and 195 (those losing at least 5% of baseline weight) were randomized.
- Main analysis used an intention-to-treat repeated-measures linear regression model with time, group, sex, age group, and time-by-group interaction; prespecified supplementary analyses included per-protocol, adjustment for initial weight loss, and multiple imputation.
## Limitations
- The paper states results may not be generalizable to older persons (>65 years), persons with BMI >43, patients with type 2 diabetes, or persons with low adherence to moderate-to-vigorous exercise or limited ability to exercise.
- The authors note that some participants missed the week-52 assessment: 166 of 195 (85%) attended the primary endpoint visit.
- Evident from the text: the trial was conducted in Denmark at two sites and in participants who first achieved at least 5% weight loss on a low-calorie diet, so applicability to broader obesity populations and to people unable to lose weight initially is not directly tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 3 Not checked · 76 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and to increased appetite. 9-11”
What the sources say
- Not checked — no full text of the sourcecites [9] source
- Not checked — no full text of the sourcecites [10] source
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The Introduction says that increased hunger and reduced satiety after weight loss are among the mechanisms favoring weight regain. It does not say that the regain is rapid, so the claim’s timing is unsupported. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Diet management programs, including the use of low-calorie mealreplacement products, can sustain low-calorie diet-induced weight loss with a small weight regain. 11,15-17”
What the sources say
- Supportedcites [11] source
The Study design describes a dietician-supported maintenance program that allowed low-calorie meal replacements after an initial very low-calorie diet. The Discussion reports that both groups maintained an approximately 12-kg loss over one year, with weight regain of 0.4 kg in the GLP-1RA group and 2.3 kg in the control group. (LLM, conf=0.90)
- Supportedcites [15] source
The Procedures describe a low-energy formula diet followed by food reintroduction and a structured weight-loss maintenance programme. The Results report that participants who engaged lost 14.5 kg during diet replacement, then regained 1.0 kg during food reintroduction and 1.9 kg during weight-loss management. These findings support the claim for this programme in people with type 2 diabetes; page numbers were not supplied. (LLM, conf=0.91)
- Supportedcites [16] source
The Methods (Interventions; page not provided) describe an 810 kcal/day programme using formula food products, followed by a weight-maintenance phase. The Results (Table 2; page not provided) show that mean weight loss in the treatment group was 15.1 kg at six months and 10.7 kg at 12 months: some weight was regained, but substantial weight loss remained. The Discussion (Implications of this research; page not provided) likewise reports average regain after the programme ended while noting that participants maintained clinically important losses. (LLM, conf=0.87)
- Supportedcites [17] source
The Study design and participants section describes an initial low-calorie formula diet followed by structured weight-maintenance support, including meal replacement when weight was regained. The Results report that the intervention group remained an average of 7.6 kg below baseline at 24 months, despite an average 2.6 kg regain between months 12 and 24. Page numbers are not available in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Furthermore, lifestyle interventions that encourage increased physical activity concurrent with calorie restriction have been shown to sustain moderate weight loss. 18,19”
What the sources say
- Supportedcites [18] source
The Methods > Interventions passage describes a program combining reduced caloric intake with increased physical activity. The Results > Weight, Waist Circumference and Fitness and Discussion passages report that participants maintained a modest average weight loss of 6.0% at the end of the trial, supporting the claim for overweight or obese adults with type 2 diabetes. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [19] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the isolated benefits of exercise to prevent weight regain after weight loss is understudied. 20”
What the sources say
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
Section 2.1 (page unavailable) says randomized trials lack convincing evidence that exercise improves weight-loss maintenance, supporting uncertainty about its benefit. But it also discusses numerous trials and does not say that the isolated benefit of exercise, as distinct from other interventions, has been understudied. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This is more than the total weight losses of approximately 10% that were obtained with 1-year diet-management programs after an initial low-calorie diet. 11,15,16,29”
What the sources say
- Supportedcites [11] source
The Methods describe an initial 8-week very-low-calorie diet followed by a 52-week weight-maintenance program. The Results report an initial 12% weight loss (about 12 kg) and a 2.3 kg regain in the control group after 52 weeks, leaving approximately 10% total weight loss. The cited paper therefore supports the comparison with a roughly 10% loss after a year of diet management. (LLM, conf=0.90)
- Supportedcites [15] source
The Procedures section describes an initial low-energy total diet replacement phase followed by food reintroduction and ongoing weight-loss maintenance. Table S1 (Additional information) reports a 9.9% mean weight loss in the intervention group at 12 months, supporting the cited figure of approximately 10%. The 16% loss with the combination is the citing paper’s comparison, not a result attributed to DiRECT. (LLM, conf=0.92)
- Supportedcites [16] source
The Methods (Interventions; page unavailable) describe an initial 810 kcal/day total diet replacement followed by food reintroduction and weight-maintenance support. The Results (Primary outcome and baseline characteristics; page unavailable) report a mean loss of 10.7 kg at 12 months from a mean starting weight of 107.9 kg in that group—approximately 10%. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [29] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
42 more claims · 2 with their cited sources checked
Create a free account to see all 92 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the overall weight loss was also minimal, since the study was focused on the weight-maintenance period following active weight loss.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“The combination group had a substantial weight reduction of −12.1 kg compared with placebo26, which might in itself increase appetite6.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Weight loss was maintained in the exercise group with a treatment effect of −5.3 kg compared with placebo26.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
41 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 4×
“Abdominal pain 46 (24) 3 (6) 13 (27) 18 (37) 12 (24)”
InfluentialMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735 · cited 4×
“Adverse event that led to the discontinuation of liraglutide or placebo 5 (3) 0 3 (6) 1 (2) 1 (2)”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Ross, R., Blair, S. N., Arena, R., Church, T. S., Després, J.-P., Franklin, B. A., Haskell, W. L., Kaminsky, L. A., Levine, B. D., Lavie, C. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000461 · Cited by 2,486
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Cited by
Items 401–500 of 526
Satti, D. I., Aronis, K. N., Berger, R. D., Calkins, H. G., & SPRAGG, D. D. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.07.005 · Cited by 1
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Galiuto, L., & Liuzzo, G. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab356
“The study of Lundgren et al.1 demonstrates that treatment with liraglutide is able to maintain weight loss, with a reduction in body fat, as compared with placebo.”
BackgroundInfluentialLes nouvelles thérapeutiques du diabète
Larger, É., Paul, M., & Alexandre‐Heymann, L. (2021) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2021.09.018
Sport plus Liraglutid – die Kombi macht’s
Krome, S. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1521-2068
Owens, D., & TOMKIN, G. H. (2021) · OBM Integrative and Complementary Medicine · doi:10.21926/obm.icm.2104048
“The new excitement is the finding that a GLP-1 agonist, in this case liraglutide, was successful in maintaining significant weight loss after a short spell of severe calorie restriction [5, 18].”
22 還元進行過程の調査 : 小型高炉による製銑過程に関する基礎研究 I(製銑, 日本鉄鋼協会第 70 回(秋季)講演大会講演論文集 (I))
大蔵, 明., カルデロン, F. P., & 松下, 幸. (1965) · 鐵と鋼 : 日本鐡鋼協會々誌
Sport plus Liraglutid – die Kombi macht's
(2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1519-0581
TOMKIN, G. H. (2021) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2021.15.555901
Möglichkeiten der Adipositastherapie in Deutschland
Holzapfel, C. (2022) · Ernährung & Medizin · doi:10.1055/a-1584-3327
Sport plus Liraglutid – die Kombi machtʼs
(2021) · Gastroenterologie up2date · doi:10.1055/a-1525-3923
(2021) · Gastroenterologie up2date · doi:10.1055/a-1532-9554
“[5] Lundgren JR, Janus C, Jensen SBK et al.”
BackgroundInfluentialThe pharmacological treatment of obesity: A historical perspective
Cuenca-Ecuador., U. C. D. C., Pacheco, A. V. G., Peláez, C. E. A., & Ortíz, R. (2022) · Gaceta Médica de Caracas · doi:10.47307/gmc.2022.130.s3.27
Pytka, M., Domin, R., Tarchalski, J., Lubarska, M., Żołyński, M., Niziński, J., Piskorski, J., Wykrętowicz, A., & Guzik, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010098 · Cited by 1
Henriksen, M., & Dai, Z. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99269-5.00003-7
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Sharma, N., & Singh, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_22
Коваль, С., Rieznik, L., Мисниченко, О., & Литвинов, В. (2023) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2023.1.08
Healthy Lifestyles for the Self-Management of Type 2 Diabetes
Galaviz, K. I., & Ali, M. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_31
Peinado, J. (2022) · Digital Commons - Andrews University (Andrews University) · doi:10.32597/dmin/760/
Renck, A. C. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-13062023-142212
INDISCRIMINATE USE OF LIRAGLUTIDE AND SEMAGLUTIDE FOR WEIGHT LOSS
Carvalho, M. L. S., Maziero, L. P., Veloso, M. K., Frigheto, F. C., de Carvalho, M. E. S. N. D., Maluf, J. S., Tavares, T. D. M., & Zanoni, R. D. (2023) · International Journal of Health Science · doi:10.22533/at.ed.1593492303076
Is combined exercise and incretin-based therapy the way forward for weight-loss maintenance?
Abildgaard, J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00873-w
DIAGNÓSTICO DA SÍNDROME METABÓLICA EM ADULTOS
Agulhan, I. D. A., Figueiredo, S. A., Grangeiro, H. C. G., Yamada, L. S., & ELEUTÉRIO-SILVA, M. A. (2023) · Anais do III Congresso Brasileiro de Saúde On-line · doi:10.51161/conbrasau2023/22715
Schirmer, M., Brandt, S., Zorn, S., & Wabitsch, M. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2079-9133 · Cited by 1
“Die Autoren schlussfolgerten, dass eine Strategie, die Bewegung und Liraglutid-Therapie kombiniert, die Gewichtsabnahme mehr als eine Behandlung mit Liraglutid allein, verbessert [38].”
Omer, A. N. C. D. S., Neto, A. L. P., Borges, A. C. R., de Almeida, A. J. M. P., Ribeiro, A. L. L., de Freitas, A. M. C. B., Tanure, A. D. L., da Silva, B. A., Pimenta, C. R., Novaes, J. V. C. D., et al. (2023) · International Journal of Health Science · doi:10.22533/at.ed.15938823181010
Medicamentos antidiabéticos utilizados com a finalidade de perda de peso
de Andrade, S. M., de Andrade, M. V. M., de Faria, P. H. A., Rosa, L. M. V., Costa, P. R. C., & PIRES, L. G. F. (2023) · Diversitas Journal · doi:10.48017/dj.v8i4.2720 · Cited by 4
Kajian Rute Alternatif Pemberian Liraglutide dalam Penanganan Diabetes dan Obesitas
Immanuel, H. (2023) · JIFFK Jurnal Ilmu Farmasi dan Farmasi Klinik · doi:10.31942/jiffk.v20i2.9299
General Treatment of Pediatric Obesity
Benavent, M. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-26727-7_9
Obésité : entre pléthore thérapeutique et questionnements nécessaires
Halimi, S. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.01.013 · Cited by 1
„Battle of Experts“: Spritze versus Sport
Sonnet, M. (2024) · Info Diabetologie · doi:10.1007/s15034-024-4966-2
Obesity management: A clinician's perspective lečenje gojaznosti iz perspective kliničara
Polovina, S. P., Šumarac-Dumanović, M., & Micić, D. (2024) · Arhiv za farmaciju · doi:10.5937/arhfarm74-50566
Langland, J. T. (2024) · JAMA · doi:10.1001/jama.2024.12065
Bando, H. (2024) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2024/asjbccr.6363
Predictors of Resistance Training Behavior among Glucagon-like Peptide 1 Medication Users
Kompf, J. M., & Rhodes, R. E. (2024) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000279
Análogos de GLP-1 e seus efeitos no emagrecimento a longo prazo: uma revisão de literatura
Alves, B. O., Santos, H. R. P., Acácio, A. F. R., Duarte, T. S., & Ribeiro, T. O. (2024) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv16n12-068
Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs
Popiela, D., Urbańska, K., Stojak, Ł., Grego, M., Kwiatkowski, F., Baczewski, M., Grego, K., & Czyż, W. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57000 · Cited by 1
(2000) · Time to knit · doi:10.1016/s1155-1941(22)83022-5
Marmett, B., da Silva, I., Lira, F. S., & Dorneles, G. P. (2025) · Translational Exercise Biomedicine · doi:10.1515/teb-2024-0039 · Cited by 5
“The overall risk of bias was characterized as high risk in Colak & Ozcelik [22] and Ozcelik et al. [24], and some concerns in Lundgren et al. [23] and Bagherzadeh-Rahmani et al. [25].”
InfluentialSábato, S., Benet, S., Rogers, A. J., Murray, T. A., Skeans, M. A., Mothe, B., Paredes, R., Mourad, A., Kiweewa, F., Kamel, D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92742-x
Self-citation(2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21835-4.00116-5
Nouveaux médicaments de l’obésité : quelle pertinence ?
Bringer, J. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.008
Physical activity promotes gut adaptation, responses to nutrients, and sensitivity to gut peptidesPreprint
Bæch‐Laursen, C., Ucin, J. V., Galsgaard, K. D., Llana, J., Kissow, H., Holst, J. J., Pedersen, B. K., & Sanchís, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.12.653520
“26 These changes may constitute the link between physical activity and energy intake.”
Self-citationPediatric Obesity Pharmacotherapy
Speakman, A., Ali-Geiger, F., & Mouzaki, M. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.05.001
Cycling of metabolic states and metabolites as drivers of atherosclerosis
Krautter, F., & Fisher, E. A. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001004
Sinha, A., Myers, E. R., & Visco, A. G. (2025) · Cureus · doi:10.7759/cureus.90764
“The mean study duration ranged from 16 to 68 weeks in the nine included articles [3-11].”
Effects of Endoscopic Sleeve Gastroplasty on Body Composition and Metabolism: An InBody Analysis
Lahooti, A., Gouda, Z., Rangwani, S. M., Johnson, K. E., Zureikat, Q. A., Aneke-Nash, C. S., Adejumo, A., Baig, M. U., Gay, D., Buckholz, A. P., et al. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08194-9
“Similarly, the combination of exercise and GLP-1 treatment resulted in approximately twice the fat mass loss and waist circumference reduction compared to either treat-ment alone while increasing lean mass [38].”
The essential role of the physiotherapy profession in incretin-based weight loss
Sampford, J., Myers-Ingram, R., Jones, G., & Cork, S. C. (2025) · Physiotherapy · doi:10.1016/j.physio.2025.101840
Shima, T., & Soya, H. (2025) · Advances in neurobiology · doi:10.1007/978-981-95-0066-6_15
Brødsgaard, R. H., Dirksen, C., Pedersen, M. M., Kirk, J. W., Duun, O. M., Finken, M. T., Bojsen-Møller, K. N., & Bandholm, T. (2025) · medRxiv · doi:10.1101/2025.10.20.25337060
“Large-scale pharmaceutical trials have demonstrated the effectiveness of GLP-1RAs in reducing weight and disease-specific symptoms and risks in populations with obesity and comorbidities, such as type 2 diabetes (25), cardiovascular disease (26), and knee osteoarthritis (27).”
InfluentialSelf-citationPodolsky, A., & Ledl-Kurkowski, E. (2025) · Springer eBooks · doi:10.1007/978-3-662-68883-0_24
Sarcopenia and obesity: Two sides of the same coin. Incretin technologies in addressing the problem
Demidova, T. Y., Толмачева, К. А., & Прилепа, С. А. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-4-06
Steven, C., Skylynn, T., Bardya, H., Megha, B., Helen, V., Lee, D., Entabi, F., & Pemminati, S. (2026) · Cureus · doi:10.7759/cureus.100704 · Cited by 2
Yamamoto, K., Kai, R., Inano, A., & Mizuno, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-35396-7
“However, glucagon-like peptide 1 receptor agonists, which lower blood glucose through a mechanism similar to DPP-4 inhibitors, have shown positive interactions with exercise training on glucose concentrations in several studies 18–20 .”
McKay, B. M., Chaar, D. E., Paquette, M. A., Vallis, M., Sherifali, D., Oh, P., Marzolini, S., Dasgupta, K., Booth, G. L., Lean, M. E. J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70510
“Structured exercise with both aerobic and resistance training can also support weight loss maintenance, 34 as well as prevent lean mass loss, 35 a concern highlighted in the recent trials on emerging glucagon-like peptide-1 (GLP-1) receptor agonist therapies with major weight loss.”
Duun, O. M., Dichman, M.-L., Lindschou, J., Scragg, J., Petersen, J. J., Bojsen-Møller, K. N., Jebb, S. A., Gluud, C., & Dirksen, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-111336
“46 47 The uptake of vitamins and minerals is more affected by RYGB than by SG, necessitating lifelong supplementation, sometimes requiring injections with vitamin B 12 and iron.”
Self-citationIntegrative Healthcare for Optimal Health
Mamtani, R., Abraham, A., Cheema, S., Chaabna, K., Mehta, D. H., & Sheikh, J. I. (2026) · F1000Research · doi:10.12688/f1000research.177886.1
Challenges in the management of obesity
Smith, B. L., May, A., Lalani, F., Hasham, S., & Presnell, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.023 · Cited by 4
Abnehmen, aber an den richtigen Stellen
Moser, J. (2026) · Info Diabetologie · doi:10.1007/s15034-025-5197-x
Katzman, J. L., Alpert, Z., Kennedy, M., Rozell, J. C., Schwarzkopf, R. M., & Lajam, C. M. (2026) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-025-06167-2
Treatment of obesity: New drugs
Berti, S., Garelli, S., & Pagotto, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00330-7
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
“Liraglutide displayed similar improvements in muscle fat infiltration [94,95].”
Martino, J. A., Oles, A. R., Rogalski, B. L., Eichinger, J. K., & Friedman, R. J. (2026) · Shoulder & Elbow · doi:10.1177/17585732261434004
Michielsen, M., Gojevic, T., Bekhuis, Y., Claes, J., Machado, F. V. C., Claessen, G., Goetschalckx, K., Hansen, D., Craemer, M. D., & Cornelissen, V. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag150
Add exercise to weight loss drugs for optimal metabolic health
Ruiz, J. R., & Butragueño, J. (2026) · BMJ · doi:10.1136/bmj.s571
Omeh, Z., Khan, T., Uthman, O., & Barber, T. M. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2656247
Daily Predictors of Resistance Training Behavior Among Glucagon-Like Peptide 1 Users
Kompf, J. M., & Rhodes, R. E. (2026) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000347
Brady, A., Roopnarinesingh, R. C., Craig, R., & Bampoe, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9197869/v1
Afşar, B., Kanbay, M., & Afşar, R. E. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106674
Wu, X., Liu, Q., Zhong, W., Zhang, L., Xu, Z., Fan, L., Zhu, J., & Su, L. (2026) · Endocrine · doi:10.1007/s12020-026-04616-5
Peng, T., Liang, W., Wei, J., Ding, N., Tang, X., & Zhang, Z. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s590529
Zadeh, A. T., Chiapparelli, E. A., Amoroso, K., Guven, A. E., Zhu, J., Köhli, P., Verna, B., Mielke, A. M., Shue, J., Burkhard, M. D., et al. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261446300 · Cited by 2
Wallentowitz, L., García, M. G., Atorrasagasti, C., Harms, C., Huhn, E. A., Roser, P., Verlohren, S., Giesen, E. M., & Blois, S. M. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10053-6 · Cited by 4
“They typically include dietary restrictions such as low-carb or low-fat diets [ 99] as well as time-restricted eating [ 100] in combination with increased physical activity, including exercise programs or step-based goals [ 101].”
Fouad, Y. M., Abdelghany, W. A., & Sheemy, R. Y. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.118303
Alvina, Jaffar, H., Onwuzo, C. N., Chaar, A., & Eisa, M. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10017-5
“…by findings of Gameil et al. which also showed a higher clinically significant risk with liraglutide compared to semaglutide and dulaglutide [7] and a randomized controlled trial by Lund-gren et al., which showed a higher incidence of cholelithiasis with liraglutide compared to placebo [17].”
Stenlid, R., Cerenius, S. Y., Torbahn, G., Aydın, B. K., Ciba, I., Vilén, H., Mörwald, K., Geiersberger, S., Roomp, K., Cadamuro, J., et al. (2026) · Obesity Facts · doi:10.1159/000552826
Gross, K., Rinne, K., Braun, A., Plappert, M., Vaitl, M., Scheibler, L., Schwensfeier, L., Riemer, L., Predel, H., Joisten, C., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113374
Malone, S. K., Glenn, A. J., Paulhamus, D. R., & Patterson, F. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105902
Alaycı, B., & Gerçek, Ö. Z. (2026) · BMC Endocrine Disorders · doi:10.21203/rs.3.rs-9973131/v1
Twf1 regulates adipocyte proliferation and differentiation through Yap nucleus accumulation
Chen, K. Y., Xu, H. Y., Lv, S., & Huang, X. (2026) · Adipocyte · doi:10.1080/21623945.2026.2694149
“Even effective treatments like GLP ‑ 1 agonists often lead to weight regain after stopping [28].”
Exercise and glucagon-like peptide 1 receptor agonists in cardiovascular disease beyond weight loss
Jordan, A. J., & McDermott, M. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01560-6
Nath, N. D., Thomas, A., & Yoshioka, J. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001834
Seeing Beyond GLP‐1: A Systems View of Sustainable Obesity Care
Mui, Y., Winkler, M. R., Ramsing, B., Palmer, A., & Altema-Johnson, D. (2026) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.70300 · Cited by 1
“In this model, dietitians provide in-dividualised nutrition counselling, meal‐planning, and physical activity guidance [64, 70]; behavioural health specialists address coping strategies, stress management, and emotional eating; and physicians monitor clinical response and adjust dosing as needed.”
Strengthening the metabolic alliance: exercise as an essential partner of obesity pharmacotherapy
Ruiz, J. R., Ciudin, A., & Butragueño, J. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01276-3
Patel, H., Babli, S. A., Shah, S., Khambholja, S. H., Lingadahalli, T. D., Villarson, C., Rizwanullah, U., Kumarsivarajah, S., Masood, A., Rahming, N., et al. (2026) · Cureus · doi:10.7759/cureus.111786
“) [19 ,”
InfluentialHundal, J., Linz, M. O., Anikreddy, S., Sengupta, S., Zhou, K., & Maiti, B. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00061 · Cited by 1
Role of incretins in Alzheimer’s disease and their impact on behavioral aspects
Yang, J., Mao, T., & Gao, L. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004195
The role of physical activity in the management of obesity
Creel, D. B. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.006
Body Composition Optimization in the Era of GLP‐1‐Based Pharmacotherapy for Obesity Management
Tinsley, G. M., Nadolsky, S., & Nadolsky, K. (2026) · Lifestyle Medicine · doi:10.1002/lim2.70067
“However, there are preliminary indications that varied exercise participation can enhance body composition changes, cardiorespiratory fitness, and weight loss maintenance in the context of treatment with the GLP-1 RA medication liraglutide [ 26, 27 ].”
Kim, H., Chae, J. H., & Moon, H. Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02141-z
“…participants were encouraged to maintain usual activity levels Grannell (2021) [35] Calorie restriction with high-protein, low GI diet (male 1500 kcal/day; female 1200 kcal/day; protein 1 g/kg BW), using two meal replacements per day plus one self-selected meal Progressive RT advised 3 days/week…”
InfluentialPhysical Activity for Weight Loss and Health Promotion
Lane‐Cordova, A. D. (2026) · Circulation · doi:10.1161/circulationaha.126.081347
Saavedra, J. M., Chen, A. S., Starr, K. N. P., & Batsis, J. A. (2026) · Obesity · doi:10.1002/oby.70203
Clinical Application and Research Progress of Novel Anti-Obesity Medications
商, 博. (2026) · Pharmacy Information · doi:10.12677/pi.2026.154043
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
“However, the combination strategy decreased body fat percentage by 3.9% points, which was approximately twice the decrease in the exercise group (−1.7% points; 95% CI: −3.2 to −0.2, p = 0.02) and the liraglutide group (−1.9% points; 95% CI: −3.3 to −0.5, p = 0.009) [65].”
InfluentialLoaiza-Giraldo, J. P., Valdivia-Arroyo, R., Greve-Quezada, V., Quivira-Muñoz, A., Silva-Perez, O., Tocornal, T. S., Bruna-Mejías, A., Nova-Baeza, P., Orellana-Donoso, M., Moya, M. P., et al. (2026) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2026.109439
“…of diabetes management remains nonpharmacological intervention, including dietary modification to optimize glycemic control, lipid profiles, and blood pressure, as well as regular physical activity to improve insulin sensitivity, manage body weight, and reduce the risk of complications [6].”
Mills, A. M., & Noble, E. E. (2026) · Appetite · doi:10.1016/j.appet.2026.108729
Piguet, C. E. M., Nucci, R., & Beaudry, J. L. (2026) · The Journal of Physiology · doi:10.1113/jp291081 · Cited by 1
Balasubaramaniam, V., Scobie, M., O’Kane, M. P. M., Graham, Y., Robertson, A. G., & Mahawar, K. K. (2026) · Nutrients · doi:10.3390/nu18162643
“Lundgren et al. reported that combining structured exercise with liraglutide resulted in greater reductions in body weight and body-fat percentage than either intervention alone, alongside improvements in HbA1c, insulin sensitivity, and cardiorespiratory fitness [75].”
Kim, B.-Y. (2026) · Healthcare · doi:10.3390/healthcare14162570
“…exercise with GLP-1 receptor agonist therapy improves the maintenance of weight loss and better preserves lean body mass than pharmacotherapy alone [42], and that such combined approaches produce greater reductions in metabolic-syndrome severity and abdominal obesity than either strategy in…”
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“Success necessitates integrating sustained high-level behavioral support (including psychological counselling and dietetic coaching) to ensure adherence to this rigorous regimen [223].”
Metadata
- Authors
- Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J.-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital–Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) — all in Denmark.
- Amager Hospital (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1719-1730
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3158123746
- Cited by
- 536
- References
- 35
- Citations by year
- 2026: 140 · 2025: 137 · 2024: 86 · 2023: 78 · 2022: 71 · 2021: 23
- FWCI
- 37.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- Helse Fonden
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Danish Diabetes Academy
- Novo Nordisk Fonden (NNF15CC0018486, NNF16OC0019968)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, weight loss maintenance, weight regain, liraglutide, physical activity, hypocaloric diet, body fat percentage, GLP-1 receptor agonists, combination therapy, metabolic health
- MeSH terms
- Liraglutide, Adipose Tissue, Adult, Combined Modality Therapy, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Weight Loss, Anti-Obesity Agents, Caloric Restriction, Body Size
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.